echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Non-targeted metabolomics studies the pathogenesis of ALS.

    JNNP: Non-targeted metabolomics studies the pathogenesis of ALS.

    • Last Update: 2020-10-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Amyotrophic lateral sclerosis (ALS) is an aggressive and fatal motor neurone degenerative disease characterized by complex genes and disease mechanisms.
    few genes are closely related to amyotrophic lateral sclerosis (ALS), the genetic causes are not clear in most cases.
    , however, the ALS gene affects multiple cellular processes, including autophagy, mitochondrial function, cytostic skeleton tissue, and axon transport.
    metabolic abnormalities can also be affected, such as amino acids, acetone acid and lipid metabolism.
    metabolites ultimately reflect the synergetic effects of genetics, metagenetics and transcriptomics, and serve as evidence of exposure to exogenous substances in the environment.
    metabolites are also a reflection of dysfunctional cellular processes and pathological states.
    For example, oxidative stress is a marker of amyotrophic lateral sclerosis, which led to a clinical trial of the antioxidant Ida Lafon, which has now been approved by the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis.
    therefore, despite the genetic and clinical heterogeneity of ALS, metabolites may be a uniform characteristic.
    metabolomics has become a new frontier in understanding pathological mechanisms, biomarkers and assessing the impact of the environment on disease.
    metabolomics is an aimless, system-wide, and simultaneous analysis of all metabolites present in the sample.
    identify diagnostic or prognostic biomarkers, understand complex pathophysiology, identify drug target candidates, or reveal potential new hypothesis generation pathways.
    metabolomic analysis can provide alS with new hypotheses, therapeutic targets, and potential biomarkers.
    : The study included 125 ALS patients and 71 control participants.
    alS and the Neurohyeth health control group were the subjects of the University of Michigan (UM).
    , all patients who have been at the University of Michigan's ALS clinic for more than 18 years and are able to communicate in English provide plasma shortly after diagnosis.
    blood plasma was also provided to control groups with gender and age matching.
    to collect demographic information about participants, such as gender, age, height, weight, and ALS disease characteristics.
    blood was taken from participants who were not asked to fast.
    non-targeted metabolomic analysis of blood using ultra-efficient liquid chromatography series mass spectrometrography (UPLC-MS/MS).
    use methanol to extract metabolites from the plasma, do not assess extraction efficiency and instrument performance.
    metabolites were then analyzed by inverse UPLC-MS/MS in positive and negative ion mode and hydro-hydro-interaction chromatography UPLC-MS/MS.
    identified a total of 1,051 known metabolites using retention time/index, mass-to-load ratio, and chromatography data.
    : 300 metabolites were identified based on gender, age, and BMI-adjusted logistic regression models.
    PLS-DA identified 295 metabolites of characteristic variable projection importance (VIP) and separated the case from the control group.
    VIP score chart shows the highest VIP.
    the highest metabolites (sub-pathways) of
    VIP include beta-diazepam (exotopic), lactic acid methylene (histamine metabolism), creatine (creatine metabolism), creatine (creatine metabolism) and 4-acetyl phthalates sulfate (external).
    This non-targeted metabolomics study found evidence of pathline abnormalities in ALS, including previously established path path paths (e.g. energy homogeneity enzymes, amino acid metabolism) and new or emerging path path paths (e.g., diglyclycelin, benzoate metabolism), which could lead to promising new target MedSci sources for disease treatment MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medicine and are not reproduced by any media, website or individual without authorization, and must be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    reproduce content at the same time does not represent the position of this site.
    leave a message here.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.